Translocation t(11;19)(q23;q13.1) without MLL Rearrangement in Acute Myeloid Leukemia: Heterogeneity of the 11q23 Breakpoints

Acta Haematol. 2015;134(2):76-9. doi: 10.1159/000371832. Epub 2015 Apr 18.

Authors

Katsuya Yamamoto¹, Shinichiro Kawamoto, Seiji Kakiuchi, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

Affiliation

¹ Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

PMID: 25895667
DOI: 10.1159/000371832

No abstract available

Publication types

Case Reports
Review

MeSH terms

Aclarubicin / therapeutic use
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chromosome Breakpoints
Chromosomes, Human, Pair 11*
Chromosomes, Human, Pair 19*
Cytarabine / therapeutic use
Fatal Outcome
Female
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / physiopathology
Myelodysplastic Syndromes / etiology
Recurrence
Translocation, Genetic*

Substances

Cytarabine
Granulocyte Colony-Stimulating Factor
Aclarubicin

Supplementary concepts

CAG protocol